Yasutoshi Sakamoto
7 Papers
1 Citations
Yasutoshi Sakamoto is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data.
Yasutoshi Sakamoto,Hideaki Bando,M. Nakamura,Hiromi Hasegawa,Takako Kuwaki,Wataru Okamoto,Hiroya Taniguchi,Yoshihiro Aoyagi,Izumi Miki,Hiroshi Uchigata,Naomi Kuramoto,Nozomu Fuse,Takayuki Yoshino,Atsushi Ohtsu +13 more
TL;DR: The SCRUM-Japan Registry as mentioned in this paper is a qualified registry utilized as external control data for regulatory submission for drug development for rare disease and rare molecular subtypes for which conducting randomized controlled trials is challenging.
12
SO-8 Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)
Hisato Kawakami,Yu Sunakawa,Eisuke Inoue,Ryoji Matoba,Kiichiro Noda,T. Sato,Chihiro Suminaka,Yasutoshi Sakamoto,R. Kawabata,Atsushi Ishiguro,Yusuke Akamaru,Yosuke Kito,Hiroshi Yabusaki,Jin Matsuyama,M. Takahashi,Akitaka Makiyama,Hidetoshi Hayashi,Kenji Chamoto,Takafumi Honjo,Kazuhiko Nakagawa,Wataru Ichikawa,Madoka Fujii +21 more
TL;DR: The DELIVER trial as discussed by the authors evaluated the association of soluble checkpoint molecules for immune checkpoint inhibitor with efficacy measures including survival in advanced gastric cancer patients treated with nivolumab monotherapy using blood samples collected from a prospective observational and translational study.
2
DJS-3 Utilizing real-world data as an external control for new drug approval in molecular subtype: experience in SCRUM-Japan Registry
TL;DR: According to PMDA's Revised Version of 'Guideline for Clinical Evaluation of Anti-Cancer Drugs', clinical evaluations by the data of single-arm phase 2 trial combining the data from disease registry can be considered in case of rare subtype categorized by gene alterations as mentioned in this paper .
323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial
Akitaka Makiyama,Kentaro Yamazaki,Manabu Shiozawa,Dai Manaka,Masahito Kotaka,Yasutoshi Sakamoto,Akio Shiomi,Yoshinori Munemoto,Toshiki Rikiyama,Mutsumi Fukunaga,Uehara Takashi,Kohei Shitara,Hironori Shinkai,Nobuyuki Tanida,Eiji Oki,T. Misumi,Eiji Sunami,Atsushi Ohtsu,Yoshihiko Maehara,Takayuki Yoshino +19 more
TL;DR: ACHIEVE-2 was conducted as one of four phase III trials for patients with high-risk stage II colon cancer (CC) investigating the duration of adjuvant (adj) oxaliplatin-based therapy in a prospective pooled analysis, IDEA collaboration as mentioned in this paper .
P-61 Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy
H. Matsuoka,Yukiya Narita,T. Misumi,Yasutoshi Sakamoto,Tsutomu Kawakami,Hiroaki Tanioka,Tomohiro Matsushima,H. Miwa,Hirokazu Shoji,Atsushi Ishiguro,Sachio Fushida,Kazuko Miura,their children Tamaki Yamada,Kaichiro Shinozaki,Tetsutaro Mizukami,Takahiro Moriwaki,Seiichiro Mitani,Mikiko Nakamura,Kei Muro,Tomohiro Nishina +19 more
TL;DR: In this paper , the authors evaluated the survival from the NIVO therapy initiation in all registered participants of the REVIVE trial and found that the survival of patients who received the best supportive care (cohort A) was compared to those who were not included in the main study, and the patients formally were registered as formal registration.